CureVac reports Q4 revenue EUR 22.6M vs. EUR 11.7M last year

“We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose. We are adapting unnecessary residual pandemic infrastructure, optimizing our workforce and aligning our structures and resources to the right size for our business scope and development priorities. Under this streamlined structure, we intend to move forward with purpose and determination,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. “As we advance our pipeline in both infectious disease and oncology, we continue to seize opportunities to accelerate development of our differentiated mRNA approach. This is most recently evidenced by our collaboration with MD Anderson, one of the world’s leading cancer centers. Further expanding such strategic collaborations and partnerships will be the key focus for Thaminda Ramanayake, who will join the management team as Chief Business Officer in June. We finished 2023 with a robust cash position of EUR 402.5 million supported in Q4 by the recognition of a EUR 15 million milestone from GSK for the start of the Phase 2 development of our joint seasonal flu program,” said Pierre Kemula, Chief Financial Officer of CureVac. “Going into 2024, we have had a strong focus on cost management and increased operational efficiency. Importantly, and despite the wind-down of the Pandemic Preparedness Agreement with the German government, these efforts enable us to extend our runway into the fourth quarter of 2025.”